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Cytochromes P450 play key roles in drug metabolism and disease
by oxidizing a wide variety of natural and xenobiotic compounds.
High-resolution crystal structures of P450cam bound to ruthenium
sensitizer-linked substrates reveal an open conformation of the
enzyme that allows substrates to access the active center via a 22-Å
deep channel. Interactions of alkyl and fluorinated biphenyl linkers
with the channel demonstrate the importance of exploiting protein
dynamics for specific inhibitor design. Large changes in peripheral
enzyme structure (F and G helices) couple to conformational
changes in active center residues (I helix) implicated in proton
pumping and dioxygen activation. Common conformational states
among P450cam and homologous enzymes indicate that static and
dynamic variability in the FyG helix region allows the 54 human
P450s to oxidize thousands of substrates.
Cytochromes P450 comprise a family of monooxygenasesthat catalyze transformations of many diverse substrates
(1). In particular, the ability of P450s to hydroxylate aliphatic
carbon by generating a reactive heme–oxygen species has
stimulated much research (R-H 1 O2 1 2H1 1 2e23 R-OH
1 H2O). Found in all phyla, P450s have the same protein fold
and cysteine-ligated heme, despite low sequence similarity
between some members (structurally similar P450cam and
P450BM-3 have only 17% sequence identity) (2). Humans have
at least 54 different P450 isozymes (http:yydrnelson.
utmem.eduyCytochromeP450.html). The human P450 iso-
zymes play key roles in steroid biosynthesis and arachidonic
acid metabolism, as well as in the transformations of xenobi-
otics in detoxification and carcinogenesis (3). Particularly
striking is the finding that P450 3A4 metabolizes up to half of
all drugs in use (4). Despite broad substrate diversity, all P450s
have significant structural constraints on their activity: P450s
must control water access to the active center to avoid the
conversion of activated dioxygen to superoxide or peroxide.
Thus, the binding sites of P450 isozymes must be structurally
diverse, yet conserve a mechanism of catalysis and solvent
exclusion. An unanswered question is how thousands of sub-
strates are metabolized by one enzyme family whose chemistry
requires significant structural constraint.
We are investigating the archetypal P450, Pseudomonas putida
P450cam, by using sensitizer-linked substrates that were de-
signed to bind the enzyme selectively and communicate elec-
tronically with the heme center by way of tethered ruthenium
tris(bipyridyl) [RuII(bpy)3]21 complexes (5, 6). Herein, we de-
scribe the structures of two such Ru-substratezP450cam conju-
gates. As predicted, the substrate moieties bind at the active
center, and the Ru-sensitizers bind near the protein surface.
Importantly, the enzyme changes conformation to accommo-
date the linkers. The open conformation we observe mimics
structures of other P450 enzymes and reveals a likely path for
substrates to access the active center. Notably, this rearrange-
ment is coupled to conformational changes of catalytically
important residues.
Materials and Methods
Crystallization and Data Collection. Purification, crystallization and
structure determination of P450camzRu-C9-Ad [C9 5
(2CH22)9, Ad 5 adamantane] have been described (5).
P450camzRu-F8bp-Ad (F8bp 5 4,49-octafluorobiphenyl) seed
crystals in the space group P1 [cell dimensions, 63.8 3 67.1 3
72.5 Å3; two molecules per asymmetric unit; Matthews coeffi-
cient (VM) 5 2.56; solvent content 5 51.9%] nucleated from
C334A P450cam separated from camphor and complexed with
stoichiometric Ru-F8bp-Ad. Hanging drops contained an equal
volume mixture of reservoir and 396 mM P450zRu-F8bp-Ad in 20
mM Hepes, 100 mM KCl, and 1 mM DTT, pH 7.5. The reservoir
(pH 6.5) contained 0.1 M sodium cacodylate, 200 mM KCl, and
8–15% (wt/vol) polyethylene glycol (PEG; molecular weight 5
8,000). Crystal nucleation was induced by setting the crystalli-
zation trays on ice for 30 min. The resulting temperature gradient
causes partial dehydration of the hanging drops. The trays were
then removed from the ice and stored at 4°C; seed crystal growth
occurred overnight. Diffraction-quality crystals were grown over
24 h by moving seed crystals into sitting drops with reservoir
PEG concentrations of 8–11%.
Two data sets were collected at the Stanford Synchrotron
Research Laboratory (SSRL). Data set 1 (1.80-Å resolution) was
collected at 100 K on beamline 9-2 (l 5 1.03 Å) at SSRL and
processed with DENZO and SCALEPACK (7). Data set 2 (1.65-Å
resolution) was collected at 100 K on beamline 9-1 (l 5 0.72 Å)
and similarly processed (Table 1).
Structure Determination of P450zRu-F8bp-Ad. An initial molecular
replacement solution (correlation coefficient 5 46.1, and Rcryst
5 S iFobsu - uFcalciyS uFobsu 5 44.7%) for diffraction data set 1
(20.0- to 3.5-Å resolution) was found with AMORE (8) by using
two probe molecules, each derived from the structure of
camphor-bound P450cam (PDB code 2cpp). The initial model
derived from molecular replacement on data set 1 was replaced
with the protein coordinates from Ru-C9-Ad-bound P450cam
(PDB code: 1qmq) by least-squares fitting and was further
improved by simulated annealing. Ru-F8bp-Ad was positioned
into the remaining difference density. Refinement was com-
pleted with data set 2 by iterative rounds of torsion-angle
molecular dynamics and positional refinement with Crystallog-
raphy & NMR System (9) and XFIT (10) amidst model rebuilding,
water molecule placement, and resolution extension to 1.65 Å.
Overall anisotropic thermal factor correction, bulk solvent cor-
rection, individual thermal factor refinement, and grouped
occupancy refinement of Ru-F8bp-Ad produced the final model
(7688 scatterers in the asymmetric unit, 2 P450zRu-F8bp-Ad
molecules, each containing a superposition of Ru-F8bp-Ad D
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and L stereoisomers; 18 residues in multiple conformations; 5
cacodylate molecules bound to cysteines 58A, 85A, 58B, 85B,
and 136B; and 693 water molecules). Noncrystallographic sym-
metry restraints were not applied between the two molecules per
asymmetric unit. The final model has excellent stereochemistry
(Table 1) with 90.5% of all residues in the most favored regions
of wyc space as defined by PROCHECK (11). The residue Glu-94
falls outside the accepted regions of wyc space because of steric
interactions with the cacodylate bound to Cys-85. Figures were
generated with BOBSCRIPT (12), MOLSCRIPT (13), RASTER3D (14),
and INSIGHT II. Molecular surfaces were calculated with MSMS
(15) and rendered with AVS (Advanced Visual Systems,
Waltham, MA).
Results and Discussion
Ru-Substrate Binding Reveals a Substrate Access Channel in P450cam.
The P450cam complexes with Ru-C9-Ad and Ru-F8bp-Ad have
strikingly similar protein conformations (Ca rms deviation 5 0.7
Å) and sensitizer-linked substrate-binding modes, despite having
crystallized in different space groups. Ru-C9-Ad and Ru-
F8bp-Ad share the same [RuII(bpy)3]21 and adamantyl function-
alities, but are linked with a nine-carbon alkyl chain in Ru-C9-Ad
and a 4,49-substituted octafluorobiphenyl in Ru-F8bp-Ad.
The ruthenium complexes bind P450cam in a channel that
likely gives natural substrates access to the buried active center
(Fig. 1). Movement of the F (residues 173–185) and G (192–214)
helices against the perpendicular I helix (234–267) retracts the
FyG loop (185–192) from the enzyme’s b-sheet domain and
thereby opens an access channel to the heme that is 22 Å deep
and 11 Å across (Fig. 2). In effect, the F and G helices translate
relative to the protein core in a ‘‘shear’’ mechanism (17), whereas
the core itself undergoes smaller motions to maintain hydro-
phobic interactions.
On opening of the access channel, the interactions of the F and
G helices with the protein core manifest in two ways: (i) the
making and breaking of salt bridges to stabilize helix juxtapo-
sition; and (ii) slight distortion of the core backbone to conserve
hydrophobic packing. Rearrangements of inter-residue salt
bridges and hydrogen bonding interactions among the F helix,
FyG loop, and the I helix facilitate sliding of the F helix relative
to the I helix. These rearrangements (Fig. 3) either exploit the
conformational f lexibility of long side chains to maintain hy-
drogen bonding interactions (e.g., Glu-171 to Arg-161, Arg-186
to Asp-251) or involve the breaking and making of hydrogen
bonds (e.g., Lys-178 to Asp-251 and Leu-250 exchanged for
Lys-178 to Glu-156).
The tendency to maintain hydrophobic packing interactions
between the G helix and both the I helix and the B9 loop (residues
89–101) causes main-chain conformational distortions within
the protein core in response to the new FyG helix positions. For
Table 1. X-ray data collection and refinement
Data set 1 Data set 2
Unit cell 64.0 67.3 72.5 Å 63.8 67.1 72.5 Å
71.3° 65.8° 62.4° 71.2° 65.2° 62.3°
Space group P1 P1
Resolution, Å 1.80 (1.86–1.80)* 1.65 (1.71–1.65)*
Rsym† 3.7 (25.6)* 3.8 (29.2)*
Completeness, % 96.8 (95.4)* 97.8 (97.0)*
Wilson B, Å2 19.0
Iys(I)‡ 21.9 (3.80)* 16.43 (1.99)*
No. molecules per unit cell 2
Rfac§ 21.0 (29.2)*
Rfree¶ 22.6 (28.7)*
rms deviation bonds, angles\ 0.007 Å, 1.2°
No. protein atoms, ^B& 6,569, 23.2 Å2
No. waters, ^B& 693, 34.3 Å2
No. Ru-F8bp-Ad atoms, ^B& 280, 25.7 Å2
Residues not modeled A1–A9, B1–B9
Additional ligands 5 cacodylate
*Highest resolution range for compiling statistics.
†Rsym 5 ((j uIj 2 ^I&uy((juIju, Ij 5 intensity of observation j.
‡Intensity signal to noise.
§R 5 ( iFobsu 2 uFcalciy( uFobsu for all reflections (no s cutoff).
¶Free R calculated against 7.4% of reflections removed at random.
\rms deviations from ideal bond and angle restraints.
Fig. 1. Comparison of P450cam bound to Ru-C9-Ad (A) and adamantane (B)
(16). On binding the Ru-substrate (L stereoisomer in blue, D stereoisomer in
green) the F and G helices (red ribbons) retract from the P450cam b-sheet
domain (gray ribbons). The adamantyl moiety binds in the same position
above the heme (yellow) as free adamantane. (C) Movement of the F, G, H, and
I helices (rotated ’180° from A and B). For comparison, P450cam bound to
camphor is shown in gray. Residues on the FyG loop move as much as 7.5 Å as
the F and G helices slide approximately one helical turn (4.5 Å) across the I
helix. The H helix (218–225) and the N terminus of the I helix (234–267) shift
with the G helix to conserve interhelical contacts.








example, the B9 loop moves to maintain packing of F87, Y96, and
F98 with F193 and Y201 on the G helix. Similarly, the numerous
contacts among the hydrophobic side chains of the F, G, and I
helices cause the N-terminal half of the I helix to rotate in
response to the translation of the F and G helices in the open
structure. As discussed below, this change in I-helix main-chain
conformation and hydrogen bonding in turn affects the confor-
mation of the active site.
The position of the F and G helices in other P450s closely
matches the conformations found in our open structures of
P450cam. Substrate-free P450BM-3 crystallizes in an open form
and P450NOR has a large, permanent access channel analogous
to that observed in the Ru-substratezP450cam structures (Fig. 4)
(18–20). The structural similarity of the open P450cam structure
with P450BM-3 and P450NOR suggests that the open confor-
mation is important for substrate binding. The Ru-substrates
stabilize a conformation that may exist only transiently for
P450cam, but is clearly stable for other cytochromes P450. Thus,
the P450 fold apparently allows an opening motion of the F and
G helices with the relative stability of open and closed forms
weighted differently among P450s.
The conformation of the FyG loop is similar in the open and
closed structures of P450cam. However, mobility of the FyG loop
is suggested by disorder in the crystal structures of P450terp and
P450 2C5 (21, 22). Furthermore, the FyG loop of CYP 119
undergoes rearrangement on binding bulky substrates (23).
Thus, FyG loop flexibility may also play an important role in
P450 substrate binding.
Solution studies support a transient open state of P450cam.
Photoacoustic calorimetry indicates that a short-lived (’130 ns)
intermediate of larger volume forms during the photolysis of
heme-bound carbon monoxide and expulsion of camphor (24).
Our structures confirm an earlier prediction based on photo-
acoustic spectroscopy that the residues Arg-186, Asp-251, Lys-
178, and Asp-182 undergo rearrangement during substrate bind-
ing (25). Furthermore, tryptophan fluorescence quenching
measurements show that substrate-free P450cam is conforma-
tionally more labile than the camphor-bound enzyme (26).
Indirect evidence also suggests an openyclosed equilibrium in
other P450s. Cooperative substrate hydroxylation, consistent
with a flexible binding site, has been observed in P450 3A4, the
most abundant hepatic P450 (27). Eukaryotic P450s, for instance
P450scc, are known to exist in multiple conformational states
(28). Drug resistance mutations in the fungal P450 CYP51 occur
in the G and H helices, far from the active site (29). Finally,
computer simulations support FyG helix fluctuations in both
P450cam and P450BM-3 (30–32).
Interactions of Ru-Substrates with P450cam. Two current problems
in drug design are (i) how to avoid the deactivation of drugs by
hepatic P450s and (ii) how to selectively inhibit a specific
pathogenic P450 (33). Our Ru-substrate complexes bind with
Fig. 2. Shape complementarity and hydrophobic interactions between
Ru-F8bp-Ad and P450cam. The water molecules (red) hydrate newly exposed
surface area in the P450camzRu-F8bp-Ad structure.
Fig. 3. Side-chain interactions in closed (A) and open (B) P450cam. The
charged residues Lys-178 (F helix), Asp-182 (F helix), Thr-185 (FyG loop), and
Arg-186 (FyG loop) alter their interactions with Asp-251, a key residue on the
I helix implicated in delivering protons to activate heme-bound dioxygen.
Alternate conformations of Arg-186 and Asp-251 are present in the Ru-C9-Ad
complex, indicating conformational mobility. The N-terminal I helix segment
translates and rotates to maintain a hydrophobic core of interdigitated
branched hydrophobic residues (Leu-246, Leu-250, and Val-247) with the F
(Leu-177, Thr-181, and Met-184) and G (Leu-200, Tyr-201, Leu-204, and Ile-208)
helices.
Fig. 4. The F, G, and I helices of P450cam in its closed (gray) and open (blue)
states compared with those of P450NOR (light blue).
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submicromolar dissociation constants, but are structurally very
different from camphor. Thus, the interactions of the Ru-
substrates with P450cam provide insight into why some P450s are
promiscuous binders and suggest how to design specific P450
isozyme inhibitors.
Our structures provide examples of rarely characterized in-
teractions among proteins, metal complexes, and fluorinated
aromatics. Both Ru-substrates bind P450cam in a similar fashion.
Notably, the ruthenium atom and adamantyl centroids are only
1.64 and 1.07 Å apart in the superimposed structures. In part, this
is because of design: Ru-F8bp-Ad was synthesized after the
crystal structure of Ru-C9-Ad was known. However, preferred
interactions between the protein and Ru-substrates lead to
similar structures.
Ru-F8bp–Ad Interactions. Although direct contacts between
[RuII(bpy)3]21 and the protein are limited, both the D and L
isomers of the complex could be discerned because of the rigidity
of Ru-F8bp-Ad (Fig. 5). There are very few crystal structures of
fluorinated aromatics bound to proteins. Phenyl and perfluoro-
phenyl functionalized molecules are known to stack in the solid
state because of favorable p–p interactions between the elec-
tron-rich phenyl groups and electron-poor perfluorophenyl
groups (35). These attractive interactions, which have been
estimated to be worth about 15 kJ/mol in vacuum, make the
hydrophobic perfluorophenyl group a potentially useful func-
tionality for drug design (36–40).
The P450camzRu-F8bp-Ad complex shows both parallel and
perpendicular stacking between the octafluorobiphenyl unit and
aromatic residues (Figs. 2 and 5). The crystal structure of a
matrix metalloproteinase inhibitor also shows a parallel stacking
interaction (3.7 Å-separation) between a pentafluorophenyl
group and a tyrosine, which contributes to the binding affinity of
the inhibitor relative to the phenyl analog (39). In contrast, the
crystal structure of a carbonic anhydrase inhibitor shows per-
pendicular stacking between a phenylalanine and a pentaflu-
orophenyl group (41). Our results further demonstrate that the
interaction between an aromatic electron donor and a fluori-
nated ring can be parallel or perpendicular and is influenced by
both the intrinsic attraction and the structural constraints im-
posed by the tertiary structure.
Ru-C9-Ad Interactions. Because of the flexibility of the alkyl chain,
the bipyridyl ligands of Ru-C9-Ad were difficult to discern in the
electron density. Anomalous scattering measurements revealed
two distinct positions for the ruthenium atom separated by ’1
Å in the access channel. The best fit to the electron density
included both D and L isomers and interactions with Tyr-29 and
Pro-187, as in the Ru-F8bp-Ad structure (Figs. 1 and 2). In
addition, a bipyridine contacts Ala-92, and an acetate molecule
(present in the crystallization solution) sandwiches between the
[RuII(bpy)3]21 unit and Phe-193. The hydrocarbon tether linking
the ruthenium complex to the adamantyl unit winds across
the side chains of Ile-395, Phe-193, Phe-87, and Tyr-96—the
same residues that contact the fluorinated biphenyl unit in
Ru-F8bp-Ad.
Tyr-96 is hydrogen bonded to the carbonyl of the Ru-C9-Ad
amide bond as it is to the camphor ketone group in the substrate
complex (42). The adamantyl unit binds in the same pocket as
in the Ru-F8bp-Ad structure but enjoys more extensive hydro-
phobic interactions with Leu-244, Thr-101, Ile-395, Val-295,
Thr-252, and the Gly-248 Ca. The strain induced by the short
separation (3.00 Å) of the adamantyl unit and heme-bound water
perhaps explains the partial low- to high-spin heme shift that
occurs on binding (data not shown).
The [RuII(bpy)3]21 moiety does not force the substrate access
channel open as it is pulled in by the adamantyl group. If the
interaction with the ruthenium complex was unfavorable the en-
zyme could push the complex into solution and close around the
alkyl chain. Instead, Fo¨rster energy transfer experiments indicate
that the ruthenium resides the same distance from the heme even
when the linker is much longer than the access channel (5). Even
in the Ru-C9-Ad structure the alkyl chain is not fully extended.
Thus, favorable binding interactions between Ru-substrate and the
enzyme likely stabilize an open conformation that already exists
transiently under normal conditions. Our structures suggest that
improved P450 inhibitors might be produced by taking advantage
of the enzyme’s intrinsic flexibility.
FyG Loop Movement Affects the P450cam Active Site. The FyG loop
movement in P450cam is coupled to changes in functionally
important residues in the active center. I-helix residues 248–252
participate in dioxygen activation (1). In particular, Thr-252,
Asp-251, and the Gly-248 peptide carbonyl play crucial roles in
the conversion of heme-bound dioxygen to high-valent iron-oxo
or peroxo species. The open structure reveals that I-helix resi-
dues also couple the coordination environment of the heme iron
to enzyme tertiary structure peripheral to the active center.
In closed P450cam, the I-helix segment adjacent to the heme
iron bulges so that the peptide carbonyl groups of residues
248–251 do not form hydrogen bonds to C-terminal peptide
nitrogens within the helix. A hydrogen bond between the
Thr-252 hydroxyl and Gly-248 carbonyl stabilizes this bulge. In
open P450cam, the bulge shifts toward the N terminus of the I
helix. To effect this change, the peptide bonds between residues
250–251 and 251–252 rotate 90° relative to the closed structure
and anneal back into the helix (Fig. 6), whereas the carbonyls of
Leu-245 and Leu-246 are no longer hydrogen bonded within the
helix but instead are bonded to a buried water molecule (Figs.
6 and 7). This shift in the I-helix bulge arises from a 1.5-Å
translation of the N-terminal half of this helix that preserves
hydrophobic contacts with the retracted conformations of the F
and G helices (Figs. 3 and 7).
The altered interactions of the F and G helices with the I helix
in open P450cam regularize the I helix to conformations similar
to those found in other P450 structures. In P450BM-3 and
P450NOR, the I-helix residues equivalent to P450cam 249–251
all have standard helical conformations. This is one more helical
residue (249) than open P450cam, two more residues than
O2–bound ferric P450cam (249 and 250), and three more
Fig. 5. Simulated-annealing omit map (Fobs 2 Fcalc) calculated with Ru-
F8bp-Ad removed from Fcalc. Electron density is shown at 1.65-Å resolution and
contoured at 2.5 s. For clarity only one isomer is shown. The bipyridyl ring
contacts Tyr-29. Phe-193 contacts one fluorinated ring with 3.4 Å between
rings, consistent with the 3.4-Å face-to-face distance observed in the
benzene–hexafluorobenzene crystal structure (34). Phe-87 contacts the
perfluorobiphenyl unit in an edge-on fashion, with the « carbon 3.5 Å from the
face of the biphenyl unit. Tyr-96 packs against the biphenyl unit in an edge-on
fashion, with fluorine–carbon contacts ranging from 3.2 to 3.9 Å.








residues than closed P450cam, where residues 249, 250, and 251
all form hydrogen bonds outside the I helix. Taken together,
these structures show that the I-helix backbone adopts different
conformations depending on the ligand bound. Importantly, the
I-helix backbone conformation controls the water structure
surrounding the heme iron (Fig. 6).
The I helix communicates changes in the F and G helices to the
coordination environment above the heme. As a result of the I-helix
conformational changes in the open structure, the Gly-248 carbonyl
is even closer to the heme iron (4.8 Å) than in either the O2 complex
(5.5 Å) or the low-spin closed conformation (6.4 Å). The resulting
short hydrogen bond (2.6 Å) from the Gly-248 carbonyl to the
iron-ligating water molecule stabilizes water-bound, low-spin, low-
potential heme in the open form of the enzyme. Tilting the
equilibrium toward water-ligated, ferric heme may help prevent
heme reduction and the subsequent production of superoxide,
peroxide, and other toxic forms of reduced dioxygen.
Solvation Changes Important for Substrate Binding and Catalysis.
Twenty-four additional ordered water molecules hydrate newly
exposed surfaces in the Ru-bound structures of P450cam (Fig. 2).
This number agrees well with earlier results that suggested the
involvement of 28 water molecules in the catalytic cycle of the
enzyme (44). Because of the motion of the F and G helices, 9 new
ordered water molecules form hydrogen bonds to Asp-251, Arg-
186, Asp-182, and Lys-178 between the F and I helices. In addition,
the F helix residues Thr-185 and Thr-181 rotate in the open
structure so that their hydroxyls can form hydrogen bonds to water.
Although Asp-251 has been implicated in proton delivery to the
active center, this residue is sequestered in the closed structure.
Hydration of Asp-251 in the open structure suggests that the altered
hydrogen bond patterns of this conformation are not only impor-
tant for substrate binding but also in facilitating proton andyor
water molecule exchange during catalysis.
Buried water molecules mediate conformational f lexibility in
proteins through their mobility and ability to switch hydrogen-
bonding partners (45). Three conserved water molecules that
have analogs in P450terp, P450eryF, and P450NOR stabilize the
disrupted I helix i to i 1 4 hydrogen bonds in both the open and
closed conformations (Fig. 7) (21, 46, 47). The role of water
molecules in facilitating the openyclosed transition of P450cam
is similar to that found in the facilitation of large-scale confor-
mational f luctuations of acetylcholinesterase (48).
Structural Flexibility Makes Cytochrome P450 a Versatile Catalyst.
The motions of the F and G helices that we observed in the
comparison of the open and closed P450cam structures, along
with similar differences in structure between substrate-bound
and free P450BM-3 (49), suggest an explanation for the extraor-
dinary substrate diversity associated with human P450s. If
P450cam, an enzyme specialized for a single small substrate,
undergoes such large motions on substrate binding, many of the
human liver isozymes may as well. In effect, the F and G helices
act as a clamp, both to fix the substrate over the heme and to
exclude excess water from the active site. Remarkably, P450cam
hydroxylates Ru-substrates when suitable electron donors are
provided (50). This observation further underlines the extraor-
dinary ability of P450s to handle widely varying substrates.
The P450 cytochromes provide yet another demonstration of the
importance of energetically low-lying conformational states in
protein function. As in P450cam, these alternative conformations
may be difficult to detect if they form and decay on a submicro-
second time scale. Our structures show that regions distant from the
active center are critical for substrate binding and catalysis in
cytochromes P450. Thus, although local structure tunes the reac-
tivity of a metallo-cofactor, the entire polypeptide generates the
dynamic properties necessary for enzymatic activity.
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Fig. 6. The active sites of P450BM-3 and P450cam (closed, dioxygen-bound, and
open conformations). Regularization of the I helix between Leu-250 and Asn-255
compensates for the loss of main-chain hydrogen bonds between Leu-245 and
Leu-250 in the open P450cam structure. Interactions with the F and G helices
break the hydrogen bond between the Asn-255 side-chain amide and the Asp-
251 carbonyl, allowing the 251–252 peptide to flip down and hydrogen bond to
the Asn-255 peptide amide. As in dioxygen-bound ferrous P450cam, this peptide
flip is accompanied by the introduction of a helix-bridging water molecule (43).
Movementof theFandGhelicesalsobreaks thehydrogenbondbetweenLys-178
and the peptide carbonyl of Leu-250, allowing the 250–251 peptide bond to flip
90° and anneal into the helix.
Fig. 7. Buried water molecules facilitate the I helix rearrangement between
open (green ribbon and red waters) and closed (gray ribbon and blue waters)
states. Note the shift of the I helix bulge and concurrent rearrangement of the
buried waters. Glu-366, a highly conserved residue among P450s, anchors the
water molecules.
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